Cancer market outlook to 2014: Competitive landscape, Marktgr? And, analysis and opportunities? Growth Pipeline Report

decade has an oncology medikament growth areas more? important pharmaceutical M? rkten with a focus on targeted agents (? developed if the treatment, preferably to target those signaling pathways that are disregulated tumors). Most innovations in oncology in the last 10 years? been driven by scientific advances, particularly in the areas of genomics, proteomics and transcriptomics. />
In the present context, successful players in the oncology protocol can predict the future development and design of major clinical trials being. In recent years, biotech firms to innovate in the field of oncology fed more? than ever. The partnership with biotech companies? a central (but expensive) source of innovation, f? A lot of pharmaceutical companies, as approximately 75% of Phase II, III and pre-registration of new drugs of biotechnological origin. />
A $ 47. 7000000000 cancer? one of the gr? Ten more? rapidly growing M? Markets in the pharmaceutical sector. The quantities of hazard concern significant investment in oncology. The main purpose driven not? the price of Kr? Fte competition, but price cuts by Kostentr? Jer despite the fact that such a unilateral married? Price reduction from Ngten Kostentr? Ger are not? never been to one of the big M de-development? rkten checked and re w? f certainly a danger? r Pr? premise on which? built the entire biopharmaceutical industry.

key features of this report epidemiological analysis and forecasts of Pr? prevalence f the most? important oncological indications? r the period 2008-14, such as lung, breast, colon, ovarian M? rkte.Prognosen distributed and analysis of key products of the cancer market over the period 2008-14 on the main elements and classes of treatments.? overview of key events in the world market, that the treatment of cancer trends and sales potential in the major impact of oncology indications f haben.Strategische analysis and growth? related company? drug from the base of Umsatzerl? s focus of the class of drugs that are currently produced and marketed portfolios and product development research.

this report Develop a taste of potential patients with the report to cover more information? important segment of the cancer, the seven grams? ten pharmaceutical geographic M? understand rkten and 10 grams? Ten companies of the segment heuteSchnell cancer, as the j? interfered with more events? long? suspicius the performance of key products, and how their face wettbewerbsf marketing? hig Ver? changes in the market for cancer Win up-to-date “Competitive Intelligence” On the subject of cancer indications, and understand the key issues important? Biotech-keys you understand what information players gr? Have YOU try potential franchise growth and how pharmaceutical companies possibility? using this M?

key market issues FDA has approved Cervarix f? r Geb? rmutterhalskrebs

In October 2009, FDA approved GSK’s Cervarix for Pr? prevention of pr? Kanzer? The sen emissions? caused by human papillomavirus (HPV) types causes 4:18 p.m. ET in women? 10-25 years. Cervarix? inclusion in the Children’s Vaccine Program? an important step to ensure the R? Redemption. Cervarix should begin by the end of 2009, faces direct competition with Merck’s Gardasil and contribute? to reduce the H? Incidence of Geb? For rmutterhalskrebs in the future. Merck’s Gardasil f gt indication of the United States of genital warts in males and M? Nnern

October 16, 2009, Gardasil has broadened the U.S. label, nnern its use in M? And the boys of et? range 9-26 years. The results of the pilot study showed an efficacy of 90 years. 4%, w? While the outside? Prevents EN L? Emissions genital HPV types 6/11/16/18. Dar? Out on Merck will also provide patient assistance program providing free vaccine Gardasil to 19 to 26 M? Uninsured men sitting rderkriterien F? But not able to provide the vaccine Ngern Verl?. The main findings of this report In 2008 sales of $ 13? anticancer mAbs huge 6 billion with a market share of 28. 6% of total sales. The key? Anticancer MAbs Keys us? the h? Sent Heren market share of this class in 2008 MabThera (11 0%), Avastin (10 3%), Herceptin (9 7%) and Erbitux (3 4%). Forecast turnover for the whole market? estimated at $ 65 Antineoplastic 2 billion worldwide 2014.Roche f? While in cancer research, and h? Lt h? Chsten market share of 29. 2% ($ 14 0BN sales) in 2008 on sales of base (MabThera, Avastin, Herceptin, Tarceva and Xeloda). Roche St rke? In the market for cancer? was the agenda? From Genentech and the acquisition of a controlling stake in Chugai, which in addition? Additional bandwidth VerfÃ? Tion has done its portfolio bernahme untermauert.Eli Lilly? From ImClone? Ht flow under high quality, innovative new therapies. The transaction allowed? immediately to Eli Lilly? Doctors and their patients a GRE? Additional portfolio f? Related oncolytic agents and targeted therapies offer einschl? Lich Gemzar, Alimta and Erbitux.

Key questions answered What are the signs of cancer growth in the segment for the period 2008-14? What companies are the winners and losers in the segment of cancer in 2008, as did the last major en-offs from companies like Roche, Sanofi-Aventis done? door, Astra Zeneca, Novartis and Eli Lilly and what company? will be key players in the segment of cancer for the period 2008-14? What are the products f generic competition? r the period 2008-14 are affected? Report: In the current decade one of the main areas of growth in the oncology pharmaceutical M? rkten with a focus on targeted agents? medikament (? whether treatments designed to target those pathways that are privileged disregulated tumors). Most innovations in oncology in the last 10 years? been driven by scientific advances, particularly in the areas of genomics, proteomics and transcriptomics. />
In the present context, successful players in the oncology protocol can predict the future development and design of major clinical trials being. In recent years, biotech firms to innovate in the field of oncology fed more? than ever. The partnership with biotech companies? a central (but expensive) source of innovation, f? A lot of pharmaceutical companies, as approximately 75% of Phase II, III and pre-registration of new drugs of biotechnological origin. />
A $ 47. 7000000000 cancer? one of the gr? Ten more? rapidly growing M? Markets in the pharmaceutical sector. The quantities of hazard concern significant investment in oncology. The main purpose driven not? the price of Kr? Fte competition, but price cuts by Kostentr? Jer despite the fact that such a unilateral married? Price reduction from the Ngten Kostentr? Ger have never been to one of the great de-developed M? rkten checked and re w? f certainly a danger? r Pr? premise on which? built the entire biopharmaceutical industry.

key features of this report epidemiological analysis and forecasts of Pr? prevalence f the most? important oncological indications? r the period 2008-14, such as lung, breast, colon, ovarian M? rkte.Prognosen distributed and analysis of key products of the cancer market over the period 2008-14 on the main elements and classes of treatments.? overview of key events in the world market, that the treatment of cancer trends and sales potential in the major impact of oncology indications f haben.Strategische analysis and growth? society? related pharmaceuticals based on Umsatzerl? s focus of the class of drugs that are currently produced and R & D portfolio of products marketed.

this report Develop a taste of potential patients with the report to cover more information? important segment of the cancer, the seven grams? ten pharmaceutical geographic M? understand rkten and 10 grams? Ten companies of the segment heuteSchnell cancer, as the j? interfered with more events? long? suspicius the performance of key products, and how their face wettbewerbsf marketing? hig Ver? changes in the market for cancer-Win up to-date “Competitive Intelligence”? information about cancer, and understand the important issues that key? Biotech-keys you readers understand what information the gr? TE potential to search for franchise growth and how pharmaceutical companies possibility? using this M?

key market issues FDA has approved Cervarix f? r Geb? rmutterhalskrebs

In October 2009, FDA approved GSK’s Cervarix for Pr? prevention of pr? Kanzer? The sen emissions? caused by human papillomavirus (HPV) types causes 4:18 p.m. ET in women? 10-25 years. Cervarix? inclusion in the Children’s Vaccine Program? an important step to ensure the R? Redemption. Cervarix should begin by the end of 2009, faces direct competition from Merck’s Gardasil and contribute? to reduce the H? Incidence of Geb? For rmutterhalskrebs in the future. Merck’s Gardasil f gt indication of the United States of genital warts in males and M? Nnern

October 16, 2009, Gardasil has broadened the U.S. label, nnern its use in M? And the boys of et? range 9-26 years. The results of the pilot study showed an efficacy of 90 years. 4%, w? While the outside? Prevents EN L? Emissions genital HPV types 6/11/16/18. Dar? Out on Merck will also provide patient assistance program providing free vaccine Gardasil to 19 to 26 M? Uninsured men sitting rderkriterien F? But not able to provide the vaccine Ngern Verl?. The main findings of this report In 2008 sales of $ 13? anticancer mAbs huge 6 billion with a market share of 28. 6% of total sales. The key? Anticancer MAbs Keys us? the h? Sent Heren market share of this class in 2008 MabThera (11 0%), Avastin (10 3%), Herceptin (9 7%) and Erbitux (3 4%). Forecast turnover for the whole market? estimated at $ 65 Antineoplastic 2 billion worldwide 2014.Roche f? While in cancer research, and h? Lt h? Chsten market share of 29. 2% ($ 14 0BN sales) in 2008 on sales of base (MabThera, Avastin, Herceptin, Tarceva and Xeloda). Roche St rke? In the market for cancer? was the agenda? From Genentech and the acquisition of a controlling stake in Chugai, which in addition? Additional bandwidth VerfÃ? Tion has done its portfolio bernahme untermauert.Eli Lilly? From ImClone? Ht flow under high quality, innovative new therapies. The transaction allowed? immediately to Eli Lilly? Doctors and their patients a GRE? Additional portfolio f? Related oncolytic agents and targeted therapies offer einschl? Lich Gemzar, Alimta and Erbitux.

Key questions answered What are the signs of cancer growth in the segment for the period 2008-14? What companies are the winners and losers in the segment of cancer in 2008, as did the last major en-offs from companies like Roche, Sanofi-Aventis done? door, Astra Zeneca, Novartis and Eli Lilly and what company? will be key players in the segment of cancer for the period 2008-14? What are the products f generic competition? r the period 2008-14 are affected?

Summary: The Cancer Market Outlook 2014

Executive Summary of Cancer Epidemiology 12 12

Global Market Analysis 13
14 Pipeline analysis 15 Competitive landscape

Chapter 1 Scope and Methodology 18 < br />
field 18. Methodology 19

Chapter 2? Overview and indications of cancer epidemiology 22

Summary 22 Introduction 23

? Overview 23, the risk of lung cancer 23 24

product? Overview 24 Diagnosis, treatment and management 25 27

epidemiology NSCLC 27

28 Forecast epidemiology 29 SCLC NSCLC
; 29

colorectal cancer, SCLC 30 31 31

? diagnosis, treatment and management overview 31 32 33

Epidemiology Epidemiology of breast cancer />
overview? 34
diagnosis, treatment and management 35 36

Epidemiology 37 Forecast epidemiology of ovarian cancer 38 38 <, br />
overview? diagnosis, treatment and management of 39

Epidemiology 40 Epidemiology 41 Forecast
Geb? rmutter and Geb? rmutterhalskrebs 42 42

? diagnosis, treatment and disposal Overview 43 44

Epidemiology Epidemiology 44 Forecast

, leukemia 45? Overview 45
diagnosis, treatment and disposal 47 48

Epidemiology Epidemiology forecasts 48

49 prostate cancer? Overview 49
diagnosis, treatment and management 50 51

Epidemiology Epidemiology 51 Forecast
Bauchspeicheldr? senkrebs 53 53

Overview? diagnosis, treatment and disposal

53 54 Epidemiology 54 Forecast epidemiology

lymphoma 56? Overview 56
diagnosis, treatment and disposal 56 57

Epidemiology Epidemiology 58 />
;
60? Diagnosis, treatment and management overview 61 62

Epidemiology Epidemiology 62 Forecast

Chapter 3 Global market analysis 66 , />
66 Summary Ins? Channel 67
market analysis by country 67
market analysis drug class 69
F? related to the dynamic brand 70
MabThera (rituximab), Roche / Genentech 71
Avastin (bevacizumab) – Roche / Genentech 73
Herceptin (trastuzumab) – Roche / Genentech / 74 Chugai
Gleevec / Glivec (imatinib) – Novartis
75 Taxotere (docetaxel) – Sanofi-Aventis 76
F? trademarks related to the type of cancer 77
, Key J? approved more events? short market life of cancer 80
Cervarix FDA f? r Geb? rmutterhalskrebs 80
nnern Gardasil Merck’s disclosure GT f U.S. of genital warts in males and M? 80
Roche’s Avastin extended the forefront of breast cancer in Japan 80
Eisai first in-house Drug File breast cancer in F major? rkten 81
v Novartis? RKT Tasigna his franchise-CML 81

82 Antineoplastics Antineoplastics competitive dynamics 82 />
mAb market antineoplastic br 86 Market dynamics Key brands analysis 86 86

antineoplastic protein kinase inhibitors 88
market dynamics 88 Key brands analysis 89

Vinca alkaloids market analysis 89 Market dynamics 89

analysis Key brands Anti-metabolites 90
90
market dynamics of 90 major brands
Analysis 90 platinum />
dynamics market analysis 92 Key brand

92 antineoplastic sales forecast 1993
cytostatic hormonal therapies 94
competitive cytostatic hormonal therapies 94 />
cytostatic gonad hormone analogue market in 1997
The dynamics of the market in 1997
Key brands analysis 97 98
;
market dynamics of aromatase 98 Key brands analysis

99 anti-androgen
101; analysis of market dynamics 101 Key brands 102

sales forecasts Cytostatic hormone therapy 103
global cancer market sales forecasts 104

Chapter 4 pipeline analysis 106

Summary 106 Introduction 107 Key trends in R & D 107
targeted therapies Ver ? change the treatment of cancer biomarkers 107
customize cancer treatment cancer vaccines 108
mean? k strengths? rpereigene immune response 109 Price /> combination treatments always the treatment of choice 110 /> Phase III and are awaiting approval 112
enzastaurin – Eli Lilly 112
BiovaxID – Biovest International, and Accentia Biopharmaceuticals
; 115 Recentin cediranib () – Astra Zeneca 117
Zactima (Vandetanib) – Astra Zeneca 120 <, br /> Axitinib (AG -13,736) – Pfizer 124
Provenge (sipuleucel -T) – Dendreon 126
UnL? NGST approved 127 drugs marketed
Arzerra (ofatumumab) – GSK / Genmab 127
Afinitor (everolimus) – Novartis 130
Iressa (gefitinib) – AstraZeneca 132
Tykerb / Tyverb (lapatinib) – GSK 133 <, br /> Votrient (pazopanib) – GSK 137
forecasts pipeline links the main factors that predict />

; competitive landscape Chapter 5142